Abstract
Tuberculosis (TB) is an infectious disease caused by the pathogen Mycobacterium tuberculosis (M. tuberculosis), killing about two million people worldwide each year. An increase in the prevalence of drug-resistant strains of M. tuberculosis in the past decades has renewed focus on the development of new drugs that can treat both drug-sensitive and resistant TB infections. M. tuberculosis evades the host immune system and drug regimes by entering dormant phase within macrophage. As a consequence, there is a pressing need for new vaccines and antimicrobials to treat persistent infections. As clinically used antibiotics target very few essential functions of mycobacterium, it is rational that identification of new targets that are essential for bacterial growth and survival can serve as starting point for designing of novel drugs to cure both drug-sensitive and resistant TB infections. With the development of molecular biology and structural biology and the availability of the genome sequence of M. tuberculosis, some success has been achieved in the identification of new targets in M. tuberculosis and their relevant inhibitors. This review summarizes about ninety important targets that participate in a range of diverse physiological processes in M. tuberculosis and seven new drugs currently in clinical phase 2 or 3 trials. In addition, promising inhibitors with novel mechanisms of action and clinical vaccine candidates are highlighted.
Keywords: Antimycobacterial, dormant, drug-resistant, inhibitors, Mycobacterium tuberculosis, new targets.
Current Drug Targets
Title:Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis
Volume: 14 Issue: 6
Author(s): Xiuming Xiong, Zhijian Xu, Zhuo Yang, Yingtao Liu, Di Wang, Mei Dong, Emily J. Parker and Weiliang Zhu
Affiliation:
Keywords: Antimycobacterial, dormant, drug-resistant, inhibitors, Mycobacterium tuberculosis, new targets.
Abstract: Tuberculosis (TB) is an infectious disease caused by the pathogen Mycobacterium tuberculosis (M. tuberculosis), killing about two million people worldwide each year. An increase in the prevalence of drug-resistant strains of M. tuberculosis in the past decades has renewed focus on the development of new drugs that can treat both drug-sensitive and resistant TB infections. M. tuberculosis evades the host immune system and drug regimes by entering dormant phase within macrophage. As a consequence, there is a pressing need for new vaccines and antimicrobials to treat persistent infections. As clinically used antibiotics target very few essential functions of mycobacterium, it is rational that identification of new targets that are essential for bacterial growth and survival can serve as starting point for designing of novel drugs to cure both drug-sensitive and resistant TB infections. With the development of molecular biology and structural biology and the availability of the genome sequence of M. tuberculosis, some success has been achieved in the identification of new targets in M. tuberculosis and their relevant inhibitors. This review summarizes about ninety important targets that participate in a range of diverse physiological processes in M. tuberculosis and seven new drugs currently in clinical phase 2 or 3 trials. In addition, promising inhibitors with novel mechanisms of action and clinical vaccine candidates are highlighted.
Export Options
About this article
Cite this article as:
Xiong Xiuming, Xu Zhijian, Yang Zhuo, Liu Yingtao, Wang Di, Dong Mei, Parker Emily J. and Zhu Weiliang, Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis, Current Drug Targets 2013; 14 (6) . https://dx.doi.org/10.2174/1389450111314060009
DOI https://dx.doi.org/10.2174/1389450111314060009 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Iron Chelation and Drug Resistance in Cancer and Tuberculosis)
Current Pharmaceutical Biotechnology Identification of Active Phytochemical from Traditional Herbal Knowledge-base Targeting Pantothenate Synthetase for Anti-tuberculosis Therapy
Letters in Drug Design & Discovery Synthetic Aspects and First-time Assessment of 2-amino-1,3-selenazoles Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Epitope-Driven TB Vaccine Development: A Streamlined Approach Using Immuno-Informatics, ELISpot Assays, and HLA Transgenic Mice
Current Molecular Medicine Synthesis of Nitrogen and Oxygen based Pyrazole Derivatives and Its Antitubercular and Antimicrobial Activity
Anti-Infective Agents Recent Advances in Chalcone-Based Anticancer Heterocycles: A Structural and Molecular Target Perspective
Current Medicinal Chemistry Deep Transfer Learning for COVID-19 Prediction: Case Study for Limited Data Problems
Current Medical Imaging Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity
Current Immunology Reviews (Discontinued) miR-202 Mediates Metabolic Shift in Lung Cancer Cells via Targeting HK2
Current Signal Transduction Therapy In vitro Synthesis, Structure Elucidation, and Antioxidant Properties of Platinum(IV)-hydrazide Complexes: Molecular Modeling of Free- Hydrazides Suggested as Potent Lipoxygenase Inhibitor
Medicinal Chemistry Impact of Structural Domains of the Heparin Binding Hemagglutinin of Mycobacterium tuberculosis on Function
Protein & Peptide Letters Drugs Against Mycobacterium tuberculosis 3-Isopropylmalate Dehydrogenase Can be Developed Using Homologous Enzymes as Surrogate Targets
Protein & Peptide Letters Microwave-Assisted Synthesis and Bioactivities of Novel Quinoline Lactones
Letters in Organic Chemistry Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Vitamin D Intervention Trials in Critical Illness
Inflammation & Allergy - Drug Targets (Discontinued) Factors Affecting Sexual Transmission of HIV-1: Current Evidence and Implications for Prevention
Current HIV Research Bacteriophages as Therapeutic Agents: Alternatives to Antibiotics
Recent Patents on Biotechnology An Overview of Zinc Oxide Nanoparticles Produced by Plant Extracts for Anti-tuberculosis Treatments
Current Medicinal Chemistry NMR Assisted Antimicrobial Peptide Designing: Structure Based Modifications and Functional Correlation of a Designed Peptide VG16KRKP
Current Medicinal Chemistry Design and In Vitro Evaluation of Five Inhibitors of Mycobacterium Tuberculosis
Letters in Drug Design & Discovery